## FORM 4

obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5

	OMB APPROVAL							
	OMB Number:	3235-0287						
	Estimated average b	urden						
-	hours per response:	0.5						

Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person NEUROCRINE BIOSCIENCES INC [ OBrien Christopher Flint Director 10% Owner NBIX ] Officer (give title Other (specify below) below) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Chief Medical Officer 12780 EL CAMINO REAL 10/16/2015 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) **SAN DIEGO** CA 92130 Form filed by One Reporting Person Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature Transaction **Execution Date** Securities Form: Direct of Indirect (D) or Indirect (I) (Instr. 4) (Month/Dav/Year) Code (Instr. Beneficially Beneficial Owned Following (Month/Dav/Year) 8) Ownership Reported (Instr. 4) (A) or (D) Transaction(s) Code Amount Price (Instr. 3 and 4) S<sup>(1)</sup> Common Stock 10/16/2015 25,000 D \$47,78(2) 125,044 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

## (e.g., puts, calls, warrants, options, convertible securities)

6. Date Exercisable and

Expiration Date (Month/Day/Year)

7. Title and

Amount of

Underlying

Security (Instr. 3

Derivative

and 4)

Securities

5. Number

Derivative

Securities

Acquired

(A) or Disposed

Transaction

Code (Instr.

		of (D) (Instr and 5	. 3, 4			,		Transaction(s) (Instr. 4)	
	Code V	/ (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Explanation of Responses:									

<sup>1.</sup> Sale of 25,000 shares of common stock issued upon vesting of 50,000 restricted stock units on October 15, 2015 to cover payroll and withholding taxes, with the balance of the shares (25,000) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of

## Remarks:

1. Title of

Derivative Security

(Instr. 3)

Conversion

or Exercise

Price of

Security

Derivative

/s/ Darin Lippoldt, Attorney-in-10/19/2015 fact

8. Price of

Derivative

Security

(Instr. 5)

9. Number of

derivative

Securities

Following

Reported

Owned

Beneficially

10.

Form:

Ownership

Direct (D)

or Indirect

(I) (Instr. 4)

11. Nature

Beneficial

(Instr. 4)

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

3A. Deemed

if any

Execution Date

(Month/Day/Year)

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

3. Transaction

(Month/Day/Year)

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$46.67 to \$49.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.